Nasdaq · CIK 0001840233
XLO Xilio Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 3, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
3
with a Form 4 at this company
Signals
Open-market buys and sells at Xilio Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 0Weak | sell 210b5-1 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | $1,774 | 1,803 | -36% | - | |
| 5Weak | sell 210b5-1 | Frankenfield Christopher James Chief Financial Officer | $6,841 | 6,954 | -36% | - | |
| 38Weak | buy | GILEAD SCIENCES, INC. owner | $1.8M | 1,759,978 | +24% | - |
Transactions
The last 10 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 1, 2025 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | MOption exercise Common Stock10b5-1 | +5,000 | - | - | 5,000 | Jan 3, 2025 |
| Jan 1, 2025 | Frankenfield Christopher James Chief Financial Officer | MOption exercise Common Stock10b5-1 | +19,375 | - | - | 19,375 | Jan 3, 2025 |
| Jan 2, 2025 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | SOpen-market sale Common stock10b5-1 | -1,803 | $0.98 | $1,774 | 3,197 | Jan 3, 2025 |
| Jan 2, 2025 | Frankenfield Christopher James Chief Financial Officer | SOpen-market sale Common stock10b5-1 | -6,954 | $0.98 | $6,841 | 12,421 | Jan 3, 2025 |
| Jan 1, 2025 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | MOption exercise Restricted Stock Unitsderivative10b5-1 | -5,000 | $0.00 | $0 | 15,000 | Jan 3, 2025 |
| Jan 1, 2025 | Frankenfield Christopher James Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -19,375 | $0.00 | $0 | 58,125 | Jan 3, 2025 |
| Jan 1, 2025 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | AGrant or award Stock Option (right to buy)derivative10b5-1 | +60,000 | $0.00 | $0 | 60,000 | Jan 3, 2025 |
| Jan 1, 2025 | Frankenfield Christopher James Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative10b5-1 | +251,000 | $0.00 | $0 | 251,000 | Jan 3, 2025 |
| Dec 18, 2024 | GILEAD SCIENCES, INC. owner | POpen-market purchase Common Stock | +1,759,978 | $1.04 | $1.8M | 9,105,451 | Dec 19, 2024 |
| Dec 18, 2024 | GILEAD SCIENCES, INC. owner | POpen-market purchase Prefunded Warrants (right to buy)derivative | +6,092,816 | $1.04 | $6.3M | 9,975,266 | Dec 19, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
- Frankenfield Christopher JamesChief Financial Officer
- GILEAD SCIENCES, INC.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.